Market Assessment, Hospital Treated COVID 19 Executive Insights Multiple Geographies 2020 Report

The treatment landscape for COVID-19 is rapidly evolving, as such, intense research is focused on approaches designed to reduce viral load and/or improve outcomes in hospitalized patients infected with SARS-CoV-2. Currently, Veklury (remdesivir) is the only approved drug for hospitalized COVID-19 patients in the United States; the agent holds a conditional marketing authorization in Europe and can be used under an exceptional approval pathway in Japan. The disease poses a high burden to the healthcare system, and presents a high unmet need. A myriad of drugs with diverse mechanisms of action are in clinical development for hospitalized COVID-19 patients. Should any of these pipeline candidates launch into the COVID-19 marketplace, it will transform the treatment landscape and help address the existing unmet need.Paste Abstract text here

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Hospital-Treated COVID-19 | Executive Insights | Multiple Geographies | 2020

Related Market Assessment Reports

Dry And Wet Age-Related Macular Degeneration – Unmet Need – Detailed, Expanded Analysis: Geographic Atrophy (US/EU)

Migraine – Geographic Focus: China – Migraine – China In-Depth (China)

Nonalcoholic Steatohepatitis – Geographic Focus – China – Nonalcoholic Steatohepatitis – China In-Depth (China)

Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)

Hepatitis B Virus – Geographic Focus: China – Hepatitis B Virus – China In-Depth – China